Put companies on watchlist
Marinomed Biotech AG
ISIN: ATMARINOMED6
WKN: A2N9MM
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Marinomed Biotech AG · ISIN: ATMARINOMED6 · EQS - adhoc news (80 News)
Country: Austria · Primary market: Austria · EQS NID: 2045241
05 December 2024 02:34PM

Marinomed Biotech AG resolves second capital increase excluding statutory subscription rights by issuing 83,750 no-par value bearer shares at an issue price of EUR 8 per share


EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Corporate Action/Capital Increase
Marinomed Biotech AG resolves second capital increase excluding statutory subscription rights by issuing 83,750 no-par value bearer shares at an issue price of EUR 8 per share

05-Dec-2024 / 14:34 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Korneuburg, Austria, December 5, 2024 - Marinomed Biotech AG (the “Company”) announces that the Management Board has resolved today to increase the Company's share capital again by EUR 83,750 to EUR 1,778,333 by issuing 83,750 new no-par value bearer shares against cash contributions (the “Second Capital Increase”). The new shares will be issued from the authorized capital 2024 under exclusion of statutory subscription rights of existing shareholders. A report on the intended exclusion of the subscription rights of existing shareholders (the “Report”) was published on the Company's website from November 28, 2024 onwards, and on the electronic announcement and information platform of the Federal Government of Austria ("EVI") on November 28, 2024. The issue price per new share is EUR 8 so that the total issue price amounts to EUR 670,000. The required Supervisory Board resolution for the Second Capital Increase under exclusion of statutory subscription rights can be passed no earlier than two weeks after publication of the Report. The Company had already provided information on a possible second capital increase in ad hoc announcements of September 2, September 15, September 18 and November 27, 2024.

All 83,750 new shares have been subscribed by a total of nine individually approached investors at these issue terms and conditions.

+++ End of ad-hoc announcement +++

 


End of Inside Information

05-Dec-2024 CET/CEST News transmitted by EQS Group AG. www.eqs.com


Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Official Market)
EQS News ID: 2045241

 
End of Announcement EQS News Service

2045241  05-Dec-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2045241&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - Marinomed Biotech AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.